Long-term safety and tolerability of JYNARQUE® (tolvaptan) in patients with ADPKD was investigated in a prospective, open-label safety study1

STUDY DESIGN

  • Subjects who completed REPRISE, the TEMPO 4:4 open-label extension, or a prior JYNARQUE trial (TEMPO 3:4 or the phase 2 NOCTURNE trial) could enroll in this phase 3, prospective, multinational, open-label safety study
  • Subjects from TEMPO 4:4 continued on the same dose of JYNARQUE in this extension. Subjects from REPRISE or prior JYNARQUE trials were initiated on JYNARQUE at a split dose of 45/15 mg/day with upward titration every 3-4 days to 60/30 or 90/30 mg/day according to tolerability. For all subjects, downward titration was permitted at the investigator's discretion
  • 1800 subjects were included in the analysis. The median JYNARQUE exposure during the extension was 651 days, and cumulative exposure was up to 11 years (n=28; 520 patients were on JYNARQUE ≥7.5 years). Assessments included monthly liver enzyme testing during the first 18 months of tolvaptan exposure and every 3 months thereafter. Additionally, subjects were asked about adverse events at each monitoring visit
  • Results were comparable to the known safety profile of tolvaptan, and no new safety signals were detected1

Impact of adverse events decreased with longer exposure to JYNARQUE

Aquaretic adverse events (AEs)* decreased with longer exposure1

Aquaretic adverse events, Graph
Aquaretic adverse events, Graph

*Increased urination includes micturition urgency, nocturia, pollakiuria, polyuria.

  • Reducing sodium and protein intake may help reduce urine volume2-4
  • Suggest carrying a water bottle everywhere to stay hydrated and avoiding drinks with high sugar content
  • Advise patients to plan ahead to find the restrooms near where they will be
  • Remind your patients that taking the first JYNARQUE dose upon waking and the second dose exactly 8 hours later may reduce the need to wake up to urinate2

Discontinuation due to adverse events decreased the longer that patients continued taking JYNARQUE1

Discontinuation due to adverse events, Graph Discontinuation due to adverse events, Graph
Discontinuation due to adverse events, Graph Discontinuation due to adverse events, Graph

Most discontinuations due to adverse events occurred in the first 18 months1

Discontinuation due to adverse events in cumulative months, Graph Discontinuation due to adverse events in cumulative months, Graph
Discontinuation due to adverse events in cumulative months, Graph Discontinuation due to adverse events in cumulative months, Graph
  • Percentages are based on the number of subjects treated for each cumulative exposure period

See data showing the long-term effects of JYNARQUE. DOWNLOAD

Certification to prescribe JYNARQUE takes approximately 10 minutes†

†Individual times may vary.

JYNARQUE REMS PROGRAM

  1. Torres VE, Chapman AB, Devuyst O, et al. Multicenter study of long-term safety of tolvaptan in later-stage autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2020;31;16(1):48-58.
  2. Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29(10):2458-2470.
  3. Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT. Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan. Am J Kidney Dis. 2019;73(3):354-362.
  4. Côté G, Asselin-Thompstone L, Mac-Way F, et al. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention. Int Urol Nephrol. 2020;52(2):343-349.

INDICATION and IMPORTANT SAFETY INFORMATION

JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

WARNING: RISK OF SERIOUS LIVER INJURY

WARNING: RISK OF SERIOUS LIVER INJURY

  • JYNARQUE® (tolvaptan) can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported
  • Measure transaminases (ALT, AST) and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter. Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of hepatic injury can mitigate, but not eliminate, the risk of serious hepatotoxicity
  • Because of the risks of serious liver injury, JYNARQUE is available only through a Risk Evaluation and Mitigation Strategy program called the JYNARQUE REMS Program

CONTRAINDICATIONS:

  • History, signs or symptoms of significant liver impairment or injury. This contraindication does not apply to uncomplicated polycystic liver disease
  • Taking strong CYP3A inhibitors
  • With uncorrected abnormal blood sodium concentrations
  • Unable to sense or respond to thirst
  • Hypovolemia
  • Hypersensitivity (e.g., anaphylaxis, rash) to JYNARQUE or any component of the product
  • Uncorrected urinary outflow obstruction
  • Anuria

Serious Liver Injury: JYNARQUE can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported in the post-marketing ADPKD experience. Discontinuation in response to laboratory abnormalities or signs or symptoms of liver injury (such as fatigue, anorexia, nausea, right upper abdominal discomfort, vomiting, fever, rash, pruritus, icterus, dark urine or jaundice) can reduce the risk of severe hepatotoxicity. To reduce the risk of significant or irreversible liver injury, assess ALT, AST and bilirubin prior to initiating JYNARQUE, at 2 weeks and 4 weeks after initiation, then monthly for 18 months and every 3 months thereafter.

Hypernatremia, Dehydration and Hypovolemia: JYNARQUE therapy increases free water clearance which can lead to dehydration, hypovolemia and hypernatremia. Instruct patients to drink water when thirsty, and throughout the day and night if awake. Monitor for weight loss, tachycardia and hypotension because they may signal dehydration. Ensure abnormalities in sodium concentrations are corrected before initiating therapy. If serum sodium increases above normal or the patient becomes hypovolemic or dehydrated and fluid intake cannot be increased, suspend JYNARQUE until serum sodium, hydration status and volume status parameters are within the normal range.

Inhibitors of CYP3A: Concomitant use of JYNARQUE with drugs that are moderate or strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, indinavir/ritonavir, ritonavir, and conivaptan) increases tolvaptan exposure. Use with strong CYP3A inhibitors is contraindicated; dose reduction of JYNARQUE is recommended for patients taking moderate CYP3A inhibitors. Patients should avoid grapefruit juice beverages while taking JYNARQUE.

Adverse Reactions: Most common observed adverse reactions with JYNARQUE (incidence >10% and at least twice that for placebo) were thirst, polyuria, nocturia, pollakiuria and polydipsia.

Other Drug Interactions:

  • Strong CYP3A Inducers: Co-administration with strong CYP3A inducers reduces exposure to JYNARQUE. Avoid concomitant use of JYNARQUE with strong CYP3A inducers
  • V2-Receptor Agonist: Tolvaptan interferes with the V2-agonist activity of desmopressin (dDAVP). Avoid concomitant use of JYNARQUE with a V2-agonist

Pregnancy and Lactation: Based on animal data, JYNARQUE may cause fetal harm. In general, JYNARQUE should be discontinued during pregnancy. Advise women not to breastfeed during treatment with JYNARQUE.

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING.